| abstract |
The present invention relates to the use of bcl-2 antisense oligomers for the treatment and prevention of disorders associated with bcl-2. These disorders include cancer, tumors, carcinomas, and disorders associated with cell proliferation. In one embodiment, the bcl-2 antisense oligomer is administered in large doses. The present invention also relates to a method of preventing or treating a disorder associated with bcl-2, in particular cancer, comprising administering a bcl-2 antisense oligomer for short periods of time. The present invention also relates to the use of bcl-2 antisense oligomers to increase the sensitivity of a subject to antitumor therapy. The present invention also relates to pharmaceutical compositions comprising one or more bcl-2 antisense oligomers, which may include one or more antitumor therapeutic agents. |